Be a Smart Investor

Friday, April 29, 2022

W.P. Carey Maintains FY22 AFFO Outlook - Update

While reporting its financial results for the first quarter on Friday, net lease real estate investment trust W.P. Carey Inc. (WPC) maintained its adjusted funds from operations or AFFO guidance for the full-year 2022 in the range of $5.18 to $5.30 per share, including Real Estate AFFO of between $5.03 and $5.15 per share, based on full-year investment volume of between $1.5 billion and $2.0 billion.

from RTT - Earnings https://ift.tt/w75rsP9
via IFTTT

Bristol-Myers Squibb Slashes FY22 EPS, Adj. EPS Outlook; Q1 Results Top Estimates

While reporting financial results for the first quarter on Friday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) slashed its earnings and adjusted earnings guidance for the full-year 2022, while maintaining annual revenue outlook.

from RTT - Earnings https://ift.tt/ZQsCepY
via IFTTT

Colgate-Palmolive Maintains FY22 Earnings, Sales Growth Outlook - Update

While reporting financial results for the fourth quarter on Friday, Colgate-Palmolive Co. (CL) maintains its earnings, adjusted earnings and sales growth guidance for the full-year 2022.

from RTT - Earnings https://ift.tt/JOq31l0
via IFTTT

Honeywell Boosts FY22 Adj. EPS, Sales Outlook - Update

While reporting financial results for the first quarter on Friday, technology company Honeywell international Inc. (HON) raised its adjusted earnings and sales guidance for the full-year 2022, based on the first-quarter performance and management's outlook for the remainder of the year.

from RTT - Earnings https://ift.tt/kKfaZJt
via IFTTT

AstraZeneca Stock Down On Weak Q1 Profit; Backs FY22 View

Shares of AstraZeneca PLC were losing more than 1 percent in London trading and around 2 percent in pre-market activity on Nasdaq after the British drug major reported Friday sharply lower profit in its first quarter, despite increased revenues. Further, the company reiterated fiscal 2022 guidance at constant exchange rates. Core earnings per share is expected to increase by a mid-to-high twenties

from RTT - Earnings https://ift.tt/oJm3kXC
via IFTTT

ACCD Guides Q1 Well Below Analysts' Estimates, ALNY Cuts Outlook, NVCR Braces For Busy Year

Alnylam Pharmaceuticals Inc. (ALNY) has lowered its 2022 guidance range for combined net product revenues based on the first quarter results. For full year 2022 the company now expects combined net product revenues to range between $870 million and $930 million, down from its prior guidance of $900 million to $1 billion.

from RTT - Earnings https://ift.tt/kpoXZm0
via IFTTT

AstraZeneca Q1 Core Profit Rises, Revenue Up 60%: Reiterates FY22 Guidance At CER

AstraZeneca PLC (AZN.L, AZN) reported that its first-quarter core earnings per share increased 20% to $1.89. Core operating profit was $3.96 billion, up 60% from prior year.

from RTT - Earnings https://ift.tt/5j1qZ9L
via IFTTT